NUVB
Nuvation Bio Inc.
Biotechnology · Healthcare · United States
4.77
close · 2026-10-29
value
18
cheaper than peers18
quality
50
stronger fundamentals50
ranked against
Biotechnology (commercial)
value
quality
161 peerswide variation
Value inputs
| measure | company | vs peers |
| price to sales | 13.64× | 48 |
| price to book | 6.57× | 29 |
| forward P/E | 128.40× | 7 |
3 of 12 measures available
Quality inputs
| measure | company | vs peers |
| revenue growth | 555.6% | 92 |
| return on equity | -47.8% | 52 |
| operating margin | -161.1% | 49 |
| debt to equity | 164.0% | 14 |
4 of 4 measures available
Facts
| market cap | $2B |
| free cash flow | -$111.7M |
| employees | 298 |
| first trade | 2020-08-26 |
| next earnings | 2026-11-04 |
| fundamentals updated | 2026-08-07 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -0.60 | -2.11 | -0.35 | -0.48 |
| free cash flow | -$181.8M | -$130.6M | -$68.1M | -$96.5M |
| net income | -$204.6M | -$567.9M | -$75.8M | -$104.2M |
| revenue | $62.9M | $7.9M | $0 | $0 |
| unusual items | -$840,000 | -$426.0M | $358,000 | $9.0M |